Head to Head Survey: AEye (NASDAQ:LIDR) vs. Evolent Health (NYSE:EVH)

AEye (NASDAQ:LIDRGet Free Report) and Evolent Health (NYSE:EVHGet Free Report) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Insider and Institutional Ownership

21.6% of AEye shares are owned by institutional investors. 11.9% of AEye shares are owned by insiders. Comparatively, 1.4% of Evolent Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for AEye and Evolent Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEye 1 0 1 0 2.00
Evolent Health 1 1 14 0 2.81

AEye currently has a consensus price target of $6.00, suggesting a potential upside of 176.50%. Evolent Health has a consensus price target of $10.71, suggesting a potential upside of 157.86%. Given AEye’s higher probable upside, analysts clearly believe AEye is more favorable than Evolent Health.

Profitability

This table compares AEye and Evolent Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AEye -19,320.88% -102.95% -74.93%
Evolent Health -6.24% 1.79% 0.65%

Earnings & Valuation

This table compares AEye and Evolent Health”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AEye $200,000.00 488.90 -$35.46 million ($2.17) -1.00
Evolent Health $2.55 billion 0.18 -$61.62 million ($1.58) -2.63

AEye has higher earnings, but lower revenue than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than AEye, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AEye has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500. Comparatively, Evolent Health has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

About AEye

(Get Free Report)

AEye, Inc., together with its subsidiaries, provides lidar systems for vehicle autonomy, advanced driver-assistance systems, and robotic vision applications in the United States, Europe, and Asia-Pacific. It offers 4Sight intelligent sensing lidar platform, including 4Sight at Design, Triggered 4Sight, Responsive 4Sight, and Predictive 4Sight; and 4Sight for automotive and industrial market. The company was formerly known as CF Finance Acquisition Corp. III and changed its name to AEye, Inc. in August 2021. AEye, Inc. was founded in 2013 and is headquartered in Dublin, California.

About Evolent Health

(Get Free Report)

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

Receive News & Ratings for AEye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEye and related companies with MarketBeat.com's FREE daily email newsletter.